Dimension Therapeutics, Inc. (NASDAQ:DMTX) was downgraded by stock analysts at Wells Fargo & Company from an “outperform” rating to a “market perform” rating in a research note issued to investors on Tuesday. They presently have a $6.00 price objective on the biotechnology company’s stock, down from their prior price objective of $9.00. Wells Fargo & Company’s price target points to a potential upside of 0.84% from the stock’s previous close.
A number of other research firms have also commented on DMTX. ValuEngine raised shares of Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 30th. Canaccord Genuity reduced their price objective on shares of Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, June 28th. Citigroup Inc. raised shares of Dimension Therapeutics from a “sell” rating to a “neutral” rating and upped their price objective for the company from $5.50 to $6.00 in a research note on Tuesday. Zacks Investment Research lowered shares of Dimension Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Finally, Cantor Fitzgerald set a $3.00 target price on Dimension Therapeutics and gave the company a “hold” rating in a report on Saturday, June 10th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. Dimension Therapeutics presently has an average rating of “Hold” and a consensus price target of $5.08.
Shares of Dimension Therapeutics (NASDAQ DMTX) traded up 0.420% during midday trading on Tuesday, hitting $5.975. 82,951 shares of the stock were exchanged. The stock’s 50-day moving average price is $4.00 and its 200 day moving average price is $2.05. Dimension Therapeutics has a one year low of $1.05 and a one year high of $8.00. The stock’s market cap is $149.69 million.
Dimension Therapeutics (NASDAQ:DMTX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.49) EPS for the quarter, meeting analysts’ consensus estimates of ($0.49). Dimension Therapeutics had a negative net margin of 358.21% and a negative return on equity of 98.72%. The company had revenue of $4.37 million during the quarter. On average, analysts anticipate that Dimension Therapeutics will post ($2.10) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Dimension Therapeutics, Inc. (DMTX) Stock Rating Lowered by Wells Fargo & Company” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/10/05/dimension-therapeutics-inc-dmtx-stock-rating-lowered-by-wells-fargo-company.html.
Several institutional investors and hedge funds have recently modified their holdings of the company. Weiss Multi Strategy Advisers LLC increased its holdings in shares of Dimension Therapeutics by 6.7% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 390,403 shares of the biotechnology company’s stock valued at $683,000 after purchasing an additional 24,489 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Dimension Therapeutics by 206.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 54,231 shares during the period. Finally, Two Sigma Securities LLC acquired a new position in shares of Dimension Therapeutics in the 1st quarter valued at about $108,000. Institutional investors own 70.75% of the company’s stock.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.